Filament’s industry-leading IP portfolio now consists of ten patents for methods of extracting and standardizing natural psychedelic compounds
Vancouver, British Columbia, November 30, 2022 – Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament”or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that it has been issued two new patents for the extraction and standardization of natural psilocybin and associated psychedelic compounds. Filament’s latest patents were issued by the United States Patent and Trademark Office (USPTO) and describe technology for transforming variable psychedelic raw materials into pharmaceutical-grade, standardized drug candidates.
"When Filament was founded, conventional wisdom held that producing stable psilocin was impossible," said Taran Grey, Director of Intellectual Property. "We have since been granted patent protection for successful production of psilocin at all stages of manufacture: from extraction to purification to standardization and beyond. For example, our latest issued patents around noningestive administration are demonstrable evidence of our team's talent for innovation. The fact that we have never had a patent application denied, compared to the industry average of a less than 50% success rate, is further validation of this talent."
Filament has developed innovative technology to extract and standardize stable doses of natural compounds from magic mushrooms. On August 3, 2021, Filament was issued the first-ever patent for the extraction and standardization of natural psilocybin. Since then, the Company has been issued a total of five patents by the USPTO and five by the Canadian Intellectual Property Office.
ABOUT FILAMENT HEALTH (OTCQB:FLHLF) (NEO:FH) (FSE:7QS)
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. We are paving the way with the first-ever natural psychedelic drug candidates.
Learn more at www.filament.health and onTwitter, Instagram and LinkedIn.
Anna Cordon, Director of Communications
FORWARD LOOKING INFORMATION
Certain statements and information contained herein may constitute “forward-looking statements” and “forward-looking information,” respectively, under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “expect”, “anticipate”, “continue”, “estimate”, “may”,“will”, “should”, “believe”, “intends”, “forecast”, “plans”, “guidance” and similar expressions are intended to identify forward-looking statements or information. The forward-looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them.Certain material factors and assumptions were applied in providing these forward-looking statements. The forward-looking statements discussed in this press release may include, but are not limited to, information concerning the impact of the patent on the Company’s business and the ability of the Company to secure future patents. Forward-looking statements regarding the Company are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements ofFilament to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including status of patent applications and the ability to secure patents. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information.Filament will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.